NO975320L - Kontinuerlige, fluorkjemiske mikrodispersjoner for avlevering av farmasöytiske midler - Google Patents

Kontinuerlige, fluorkjemiske mikrodispersjoner for avlevering av farmasöytiske midler

Info

Publication number
NO975320L
NO975320L NO975320A NO975320A NO975320L NO 975320 L NO975320 L NO 975320L NO 975320 A NO975320 A NO 975320A NO 975320 A NO975320 A NO 975320A NO 975320 L NO975320 L NO 975320L
Authority
NO
Norway
Prior art keywords
pharmaceutical
pharmaceutical composition
delivery
pharmaceutical agents
preparing
Prior art date
Application number
NO975320A
Other languages
English (en)
Other versions
NO975320D0 (no
Inventor
Leo A Trevino
Luis A Dellamary
Thomas E Tarara
Jeffry G Weers
Helen M Ranney
Original Assignee
Alliance Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alliance Pharma filed Critical Alliance Pharma
Publication of NO975320D0 publication Critical patent/NO975320D0/no
Publication of NO975320L publication Critical patent/NO975320L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

En fremgangsmåte for fremstilling av en farmasøytisk mikrodlspers^on som viser forbedret blotllgjengellghet, omfatter: å tilveiebringe en termodynamisk stabil, farmasøytisk blanding omfattende minst et farmasøytisk middel inn- arbeidet l en fysiologisk akseptabel, nytende bærer, Idet bæreren består av en eller flere lipofile Huor- forbindelser og minst et ikke-fluorert medoppløsnlngsmlddel; og å kombinere den stabile, farmasøytiske blanding med en mengde av minst et nuorkjemlsk fortynnlngsmiddel tilstrekkelig til å initiere faseseparering for nevnte minst ene farmasøytiske middel fra den termodynamisk stabile, farmasøytiske blanding der en farmasøytisk mikrodispersjon dannes. Det beskrives videre mikrodlspergerte, farmasøytiske preparater og en kit for å fremstille slike preparater.
NO975320A 1995-06-07 1997-11-19 Kontinuerlige, fluorkjemiske mikrodispersjoner for avlevering av farmasöytiske midler NO975320L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/482,176 US5667809A (en) 1995-06-07 1995-06-07 Continuous fluorochemical microdispersions for the delivery of lipophilic pharmaceutical agents
PCT/US1996/009081 WO1996040053A1 (en) 1995-06-07 1996-06-05 Continuous fluorochemical microdispersions for the delivery of pharmaceutical agents

Publications (2)

Publication Number Publication Date
NO975320D0 NO975320D0 (no) 1997-11-19
NO975320L true NO975320L (no) 1998-01-27

Family

ID=23915021

Family Applications (1)

Application Number Title Priority Date Filing Date
NO975320A NO975320L (no) 1995-06-07 1997-11-19 Kontinuerlige, fluorkjemiske mikrodispersjoner for avlevering av farmasöytiske midler

Country Status (18)

Country Link
US (1) US5667809A (no)
EP (1) EP0831770B1 (no)
JP (1) JPH11506783A (no)
KR (1) KR100454377B1 (no)
CN (1) CN1192135A (no)
AT (1) ATE195415T1 (no)
AU (1) AU721759B2 (no)
CA (1) CA2222081A1 (no)
DE (1) DE69609834T2 (no)
DK (1) DK0831770T3 (no)
ES (1) ES2150674T3 (no)
GR (1) GR3034657T3 (no)
HU (1) HUP9900872A2 (no)
IL (1) IL122241A0 (no)
NO (1) NO975320L (no)
PL (1) PL323829A1 (no)
PT (1) PT831770E (no)
WO (1) WO1996040053A1 (no)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3211740B2 (ja) * 1997-08-28 2001-09-25 ダイキン工業株式会社 化粧料
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6433040B1 (en) * 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US6946117B1 (en) 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US7097849B2 (en) 1998-08-19 2006-08-29 Jagotec Ag Injectable aqueous dispersions of propofol
US6410255B1 (en) * 1999-05-05 2002-06-25 Aurora Biosciences Corporation Optical probes and assays
KR100840925B1 (ko) 1999-05-14 2008-06-24 니리어스 파마슈티컬즈, 인크. 신규한 인터루킨-1 및 종양사멸인자-α의 조절인자들, 상기조절인자들의 합성 및 상기 조절인자들의 사용 방법
DE60139544D1 (de) 2000-02-23 2009-09-24 Life Technologies Corp Veränderte, fluoreszierende proteine
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
DK1280520T4 (en) 2000-05-10 2018-06-25 Novartis Ag Phospholipid based powders for drug delivery
ES2402045T3 (es) * 2000-11-16 2013-04-26 The Regents Of The University Of California Taxón de actionomiceto marino para el descubrimiento de fármacos y de productos de fermentación
US7037528B2 (en) 2000-12-22 2006-05-02 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US7193084B2 (en) 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US6977085B2 (en) 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US6884436B2 (en) 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US6951656B2 (en) 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US20050048126A1 (en) 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US7244703B2 (en) * 2001-06-22 2007-07-17 Bentley Pharmaceuticals, Inc. Pharmaceutical compositions and methods for peptide treatment
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
EP1429749A2 (en) 2001-09-26 2004-06-23 Baxter International Inc. Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
US7112340B2 (en) 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
WO2003053411A1 (en) * 2001-12-19 2003-07-03 Nektar Therapeutics Pulmonary delivery of aminoglycosides
US7176232B2 (en) * 2002-06-24 2007-02-13 The Regents Of The University Of California Salinosporamides and methods for use thereof
WO2004034970A2 (en) * 2002-09-27 2004-04-29 Nereus Pharmaceuticals, Inc. Macrocyclic lactams
GB0307403D0 (en) * 2003-03-31 2003-05-07 Medical Res Council Selection by compartmentalised screening
NZ544858A (en) * 2003-06-20 2009-07-31 Univ California Salinosporamides and methods for use thereof
KR20060026052A (ko) * 2003-06-20 2006-03-22 니리어스 파마슈티컬즈, 인코퍼레이션 암, 염증 및 감염성 질환의 치료를 위한 [3.2.0]헤테로사이클릭 화합물 및 그 유사체의 사용방법
US7619059B2 (en) 2003-07-29 2009-11-17 Life Technologies Corporation Bimolecular optical probes
US7727752B2 (en) 2003-07-29 2010-06-01 Life Technologies Corporation Kinase and phosphatase assays
CA2445420A1 (en) 2003-07-29 2005-01-29 Invitrogen Corporation Kinase and phosphatase assays
CN101829319A (zh) * 2003-12-08 2010-09-15 Cpex药品公司 用于胰岛素治疗的药用组合物及方法
EP1711486B1 (en) * 2004-01-23 2011-05-11 Nereus Pharmaceuticals, Inc. Bis-indole pyrroles useful as antimicrobial agents
US7579371B2 (en) 2004-04-30 2009-08-25 Nereus Pharmaceuticals, Inc. Methods of using [3.2.0] heterocyclic compounds and analogs thereof
US7276530B2 (en) 2004-04-30 2007-10-02 Nereus Pharmaceuticals, Inc. [3.2.0] Heterocyclic compounds and methods of using the same
EP1830838B1 (en) 2004-12-03 2012-10-03 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating neoplastic diseases
DE102005009194B4 (de) * 2005-03-01 2006-12-14 Hpp-Hommel Pharmaceuticals Production Gmbh Verfahren zur Herstellung von polymorph stabilem Triamcinolonacetonid
AU2006276274B2 (en) 2005-07-21 2012-03-29 Nereus Pharmaceuticals, Inc. Interleukin-1 and tumor necrosis factor-a modulators; syntheses of such modulators and methods of using such modulators
US7319570B2 (en) 2005-09-19 2008-01-15 Seagate Technology Llc Random vibration and shock compensator using a disturbance observer
US7824698B2 (en) * 2007-02-02 2010-11-02 Nereus Pharmaceuticals, Inc. Lyophilized formulations of Salinosporamide A
US8426467B2 (en) 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
US8722736B2 (en) 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
US20090017167A1 (en) * 2007-07-11 2009-01-15 Herbalife International Inc. Mixture and beverage made therefrom for protecting cellular hydration
US8394816B2 (en) * 2007-12-07 2013-03-12 Irene Ghobrial Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia
US7910616B2 (en) 2008-05-12 2011-03-22 Nereus Pharmaceuticals, Inc. Proteasome inhibitors
EP2123256A1 (en) * 2008-05-19 2009-11-25 Ruhr-Universität Bochum Perfluorcarbon nanoemulsions with endocytosis enhancing surface for gene-transfer
BR112012023421B1 (pt) 2010-03-17 2021-09-14 Novaliq Gmbh Composição farmacêutica para tratamento de aumento de pressão intraocular
EP2444063A1 (en) * 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
ES2962524T3 (es) * 2011-05-25 2024-03-19 Dermaliq Therapeutics Inc Composición farmacéutica tópica a base de alcanos semifluorados
ES2617968T3 (es) 2011-05-25 2017-06-20 Novaliq Gmbh Composición farmacéutica para la administración a uñas
JP5902405B2 (ja) 2011-06-15 2016-04-13 日本オーチス・エレベータ株式会社 エレベータ装置
DK2806886T3 (en) 2012-01-23 2017-06-06 Novaliq Gmbh STABILIZED PROTEIN COMPOSITIONS BASED ON SEMIFLUORED ALKANES
CN113679699B (zh) 2012-09-12 2022-10-28 诺瓦利克有限责任公司 包含半氟化烷烃的混合物的组合物
BR122019024319B1 (pt) 2012-09-12 2022-09-27 Novaliq Gmbh Uso de composições de alcano semifluorado na fabricação de um medicamento para o tratamento de uma condição associada com queratoconjuntivite seca
BR112016001522B1 (pt) 2013-07-23 2019-10-01 Novaliq Gmbh Composições de anticorpo estabilizado
MX372723B (es) 2014-09-02 2020-06-19 Bhupinder Singh Métodos para marcar una molécula deuterada o no deuterada y formulaciones farmacéuticas para tratamiento.
CA2963923A1 (en) 2014-10-08 2016-04-14 Pacific Northwest Research Institute Methods and compounds for increasing the potency of antifungal agents
KR102584063B1 (ko) 2015-09-30 2023-09-27 노바리크 게엠베하 부분불소화 화합물
DK3355990T3 (da) 2015-09-30 2019-09-16 Novaliq Gmbh Semifluorinerede forbindelser og disses sammensætninger
US10507132B2 (en) 2016-06-23 2019-12-17 Novaliq Gmbh Topical administration method
AU2017329772B2 (en) 2016-09-22 2023-02-02 Novaliq Gmbh Pharmaceutical compositions for use in the therapy of blepharitis
MX2019003364A (es) 2016-09-23 2019-10-02 Novaliq Gmbh Composiciones oftalmicas que comprenden ciclosporina.
CA3045743C (en) 2016-12-23 2023-08-29 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
MX388460B (es) 2017-04-21 2025-03-20 Dermaliq Therapeutics Inc Composiciones de yodo.
WO2018206656A1 (en) 2017-05-12 2018-11-15 Novaliq Gmbh Pharmaceutical compositions comprosing semifluorinated alkanes for the treatment of contact lense-related conditions
KR20200059272A (ko) 2017-09-27 2020-05-28 노바리크 게엠베하 안구 질환의 치료에서의 사용을 위한 라타노프로스트를 포함하는 안과적 조성물
CN119909046A (zh) 2017-10-04 2025-05-02 诺瓦利克有限责任公司 包含f6h8的眼用组合物
MX2020009132A (es) 2018-03-02 2020-12-11 Novaliq Gmbh Composiciones farmaceuticas que comprenden nebivolol.
MX2020010036A (es) 2018-03-28 2021-03-02 Herbalife Int Of America Inc Acetilacion de polisacaridos.
WO2019206956A1 (en) 2018-04-27 2019-10-31 Novaliq Gmbh Ophthalmic compositions comprising tafluprost for the treatment of glaucoma
CA3112504A1 (en) 2018-09-27 2020-04-02 Novaliq Gmbh Lipid barrier repair
WO2020064556A1 (en) 2018-09-27 2020-04-02 Novaliq Gmbh Topical sunscreen formulation
AU2019358249B2 (en) 2018-10-12 2024-02-22 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
US12397039B2 (en) 2019-02-13 2025-08-26 Novaliq Gmbh Compositions and methods for the treatment of ocular neovascularization
AU2020340561B2 (en) 2019-09-06 2026-01-22 Novaliq Gmbh Ophthalmic composition for the treatment of uveitis
WO2024173418A1 (en) 2023-02-16 2024-08-22 Infinitum Health, Llc Methods of inhibiting cancer growth and inhibiting viral infections

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3975512A (en) * 1970-12-21 1976-08-17 University Of Illinois Foundation Non-toxic brominated perfluorocarbons radiopaque agents
GB8501015D0 (en) * 1985-01-16 1985-02-20 Riker Laboratories Inc Drug
US5284645A (en) * 1987-08-05 1994-02-08 Alliance Pharmaceutical Corp. Fluorocarbon emulsions containing amino acid based anti-inflamatory agents and buffer systems
US4987154A (en) * 1986-01-14 1991-01-22 Alliance Pharmaceutical Corp. Biocompatible, stable and concentrated fluorocarbon emulsions for contrast enhancement and oxygen transport in internal animal use
FR2602774B1 (fr) * 1986-07-29 1990-10-19 Atta Nouvelles molecules amphiphiles polyhydroxylees et perfluoroalkylees ayant des proprietes tensioactives
FR2620445B1 (fr) * 1987-09-16 1990-07-20 Centre Nat Rech Scient Nouveaux derives fluores d'acides amines, utilisables en particulier comme agents tensioactifs ou cotensioactifs et preparations a usage biomedical comprenant ces derives
US5114703A (en) * 1989-05-30 1992-05-19 Alliance Pharmaceutical Corp. Percutaneous lymphography using particulate fluorocarbon emulsions
WO1990015807A1 (en) * 1989-06-22 1990-12-27 Applications Et Transferts De Technologies Avancées Fluorine and phosphorous-containing amphiphilic molecules with surfactant properties
FR2665705B1 (fr) * 1990-08-09 1993-07-30 Atta Nouveaux derives fluores amphiphiles a structure telomere, leur procede de preparation et leur utilisation dans des preparations a usage biomedical.
US5230884A (en) * 1990-09-11 1993-07-27 University Of Wales College Of Cardiff Aerosol formulations including proteins and peptides solubilized in reverse micelles and process for making the aerosol formulations
US5292499A (en) * 1990-09-11 1994-03-08 University Of Wales College Of Cardiff Method of preparing medical aerosol formulations including drug dissolved in reverse micelles
US5173298A (en) * 1990-09-27 1992-12-22 Allergan, Inc. Nonaqueous fluorinated drug delivery vehicle suspensions
US5496535A (en) * 1991-04-12 1996-03-05 Alliance Pharmaceutical Corp. Fluorocarbon contrast media for use with MRI and radiographic imaging
FR2679150A1 (fr) * 1991-07-17 1993-01-22 Atta Preparations comprenant un fluorocarbure ou compose hautement fluore et un compose organique lipophile-fluorophile, et leurs utilisations.
WO1994014415A1 (en) * 1992-12-24 1994-07-07 Hemagen/Pfc Fluorocarbon emulsions
FR2700696B1 (fr) * 1993-01-28 1995-04-07 Atta Dispersions, émulsions, microémulsions, gels et compositions à usage biomédical comprenant un composé organique fluoré iodé, utilisables notamment comme agent de contraste.
FR2720943B1 (fr) * 1994-06-09 1996-08-23 Applic Transferts Technolo Emulsions inverses stables à forte concentration en composé(s) fluoré(s) et leur utilisation pour l'administration pulmonaire de médicaments et pour la fabrication d'émulsions multiples.

Also Published As

Publication number Publication date
WO1996040053A1 (en) 1996-12-19
ATE195415T1 (de) 2000-09-15
JPH11506783A (ja) 1999-06-15
PT831770E (pt) 2000-11-30
EP0831770A1 (en) 1998-04-01
GR3034657T3 (en) 2001-01-31
KR100454377B1 (ko) 2005-08-04
PL323829A1 (en) 1998-04-27
AU721759B2 (en) 2000-07-13
HUP9900872A2 (hu) 1999-08-30
US5667809A (en) 1997-09-16
ES2150674T3 (es) 2000-12-01
DE69609834D1 (de) 2000-09-21
MX9709690A (es) 1998-03-29
DE69609834T2 (de) 2000-12-21
CN1192135A (zh) 1998-09-02
CA2222081A1 (en) 1996-12-19
NO975320D0 (no) 1997-11-19
KR19990022587A (ko) 1999-03-25
EP0831770B1 (en) 2000-08-16
DK0831770T3 (da) 2000-12-18
AU6049496A (en) 1996-12-30
IL122241A0 (en) 1998-04-05

Similar Documents

Publication Publication Date Title
NO975320L (no) Kontinuerlige, fluorkjemiske mikrodispersjoner for avlevering av farmasöytiske midler
NO20100034L (no) Fenofibrat farmasoytisk blanding som har hoy biotilgjengelighet og fremgangsmate for fremstilling av den
CA2411153A1 (en) Method for preparing a composition
NO954245L (no) Cyklosporinholdig pulverblanding
NO940940L (no) Sulfonat og karbamatderivater av 3-aroylbenzo[bÅtiofener
IL131609A0 (en) Hydrophilic binary systems for the administration of cyclosporine
HUP0204143A2 (en) Tricyclic 1-benzylpyrazoles-3-carboxylic acid derivatives, preparation of the compounds, their use and pharmaceutical compositions containing them
MY145753A (en) Novel cyclosporin analog formulations
SI0999838T1 (en) Self-emulsifying formulation for lipophilic compounds
NO974104L (no) Faste diacyl-organiske peroksyd-dispersjoner
AU7912598A (en) Biphasic multicomponent pharmaceutical dosage forms containing substanc es able to modify the partitioning of drugs
AU1286001A (en) Pyrazolecarboxylic acid tricyclic derivatives, preparation and pharmaceutical compositions containing same
RU94041210A (ru) [/бензодиоксан, бензофуран или бензопиран/-алкиламино]-алкилзамещенные гуанидины в качестве селективных сосудосуживающих средств, способ их получения, промежуточное для них, композиция и способ ее получения
NO951422L (no) Farmasöytiske sammensetninger for behandling av osteoporose
EA200000360A1 (ru) Оральные композиции левосимендана
YU24402A (sh) 2'-supstituisani 1,1'-bifenil-2-karbonamidi, postupak za njihovu proizvodnju, njihova primena kao leka kao i farmaceutski preparati koji sadrže ta jedinjenja
NO995928L (no) Alfa-1-antitrypsin-preparater samt fremgangsmåte ved fremstilling derav
DK0754190T3 (da) En equilin-dobbeltbindingsisomer fra syreisomeriseringen af equilin
KR940703651A (ko) 리포솜 이트라코나졸 제제[liposomal itraconazole formula-tions]
DK0630365T3 (da) Fremgangsmåde til fremstilling af beta-phenylisoserin og analoge deraf
AU3777197A (en) Cyclosporin formulation
JP2002536328A5 (no)
PL338294A1 (en) Derivatives of streptogramins, method of obtaining them and compositions containing such derivatives
EP0056681A3 (en) Levonantradol and n-methyllevonantradol formulations
Hotta Tsuchiya, K.: Kartini's Image of Java's Landscape

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application